Patient-friendly, non-technical summary of research papers

September 2026 Research Update

This report covers research on Hurler syndrome published in PubMed in September 2026. For other months, see all research updates.

Last update: October 4, 2026

At a glance

Blood smear clue

A routine blood smear prompted targeted MPS I testing.

Enzyme and gene results

Low enzyme activity and IDUA changes supported MPS I.

Laronidase treatment

In one child, laronidase was linked to steadier body symptoms.

Breathing changes

In this case, breathing symptoms improved after treatment started.

Finding MPS I in overlap

This month highlighted how MPS I can be missed when another genetic diagnosis overlaps. The evidence came from a single case report that linked a blood-smear clue to testing and follow-up after treatment.

Overview

This month had one published case report about Hurler syndrome (MPS I). The main message was about recognition when symptoms overlap with another genetic condition.

In the report, a child already diagnosed with Wolf-Hirschhorn syndrome was later found to also have MPS I. A clue on a routine blood smear raised concern for a lysosomal storage disorder. This led to targeted testing that confirmed low alpha-L-iduronidase activity and IDUA gene changes consistent with MPS I.

After laronidase enzyme replacement therapy started, the report described stabilization of body-related MPS I features. It also described improved breathing symptoms. Urine glycosaminoglycan levels moved down toward the normal range for age.

The infusions were described as well tolerated in this one child, with no infusion reactions reported. Because this is a single case, it mainly shows how MPS I can be missed when another diagnosis partly explains the symptoms.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Hurler syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month included one case showing how Hurler syndrome (MPS I) can be overlooked when a child already has another genetic condition with overlapping symptoms. The main new point is that a simple lab clue on a blood smear led to targeted MPS I testing, which then confirmed alpha-L-iduronidase deficiency and IDUA gene changes. In this report, recognizing the MPS I piece mattered because specific treatment was started and the child was followed for changes in symptoms.

In the reported child, metachromatic inclusions in lymphocytes (an abnormal appearance of some white blood cells) raised concern for a lysosomal storage disorder, prompting urine and enzyme testing. Testing showed high urinary glycosaminoglycans and low alpha-L-iduronidase activity, and genetic testing found biallelic IDUA mutations alongside a 4p deletion consistent with Wolf-Hirschhorn syndrome. This combination explained why symptoms could look mixed and why MPS I was not obvious at first.

After enzyme replacement therapy with laronidase was started, the report described stabilization of somatic (body) MPS I features and improved respiratory symptoms, along with urinary glycosaminoglycans decreasing toward an age-adjusted normal range. The infusion treatments were described as well tolerated in this single patient, with no infusion-associated reactions reported. Because this is one child, it shows what is possible in an individual situation rather than predicting what will happen for others.

For families, this report mainly adds awareness that MPS I can be present even when another diagnosis already explains part of a childs symptoms, especially when signs overlap (such as developmental delay or breathing problems). The evidence here is early and based on one patient, so it does not change what is expected for most people with Hurler syndrome. What it does clarify is that certain lab or clinical clues can trigger targeted MPS I testing, and that confirming MPS I can open the door to monitoring disease markers and using MPS I-specific therapies in situations where the diagnosis might otherwise be missed.

Limitations

Only one case report was published this month.
Findings from one child cannot predict what will happen for others.
The child had another genetic condition, so symptoms and response may not generalize.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.